John L. Higgins
2021
In 2021, John L. Higgins earned a total compensation of $9.6M as Chief Executive Officer at Ligand Pharmaceuticals, a 64% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $522,438 |
---|---|
Option Awards | $2,344,512 |
Salary | $696,583 |
Stock Awards | $6,016,298 |
Other | $7,380 |
Total | $9,587,211 |
Higgins received $6M in stock awards, accounting for 63% of the total pay in 2021.
Higgins also received $522.4K in non-equity incentive plan, $2.3M in option awards, $696.6K in salary and $7.4K in other compensation.
Rankings
In 2021, John L. Higgins' compensation ranked 1,113th out of 12,415 executives tracked by ExecPay. In other words, Higgins earned more than 91.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,113 | 91st |
Manufacturing | 384 | 93rd |
Chemicals And Allied Products | 141 | 94th |
Drugs | 118 | 94th |
Pharmaceutical Preparations | 79 | 95th |
Higgins' colleagues
We found three more compensation records of executives who worked with John L. Higgins at Ligand Pharmaceuticals in 2021.